Compare SPNS & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPNS | AVDL |
|---|---|---|
| Founded | 1982 | 2015 |
| Country | Israel | Ireland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.1B |
| IPO Year | 1992 | 1996 |
| Metric | SPNS | AVDL |
|---|---|---|
| Price | $43.31 | $21.34 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $31.33 | $18.38 |
| AVG Volume (30 Days) | 397.1K | ★ 2.8M |
| Earning Date | 11-13-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.39% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $564,331,000.00 | $248,517,000.00 |
| Revenue This Year | $8.80 | $65.47 |
| Revenue Next Year | $6.98 | $30.88 |
| P/E Ratio | $37.67 | ★ N/A |
| Revenue Growth | 4.71 | ★ 79.88 |
| 52 Week Low | $23.69 | $6.38 |
| 52 Week High | $43.36 | $23.57 |
| Indicator | SPNS | AVDL |
|---|---|---|
| Relative Strength Index (RSI) | 68.47 | 59.01 |
| Support Level | $43.27 | $21.32 |
| Resistance Level | $43.36 | $21.62 |
| Average True Range (ATR) | 0.09 | 0.34 |
| MACD | -0.00 | -0.31 |
| Stochastic Oscillator | 91.12 | 6.90 |
Sapiens International Corp NV is a provider of software solutions for the insurance industry, with an emerging focus on the financial services sector. The company offers software, solutions, and professional services for property & casualty (P&C); reinsurance; life, pension & annuity (L&A); workers' compensation (WC); medical professional liability (MPL); financial & compliance (F&C); and decision modeling for both insurance and financial markets. The group also provides services for project delivery and implementation services, for its Software Solutions portfolio. Geographically, it operates in the region of North America, Rest of the World, and Europe. It generates revenue from Europe.
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.